Trial Profile

A Phase II Study of Pembrolizumab in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse Events

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma
Focus Adverse reactions

Most Recent Events

19 Mar 2024 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
19 Mar 2024 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2025.
06 Apr 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com